Literature DB >> 7852858

In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism.

K Ikewaki1, D J Rader, L A Zech, H B Brewer.   

Abstract

The metabolism of high density lipoproteins (HDL) is tightly linked to the metabolism of apoB-containing lipoproteins through the exchange and transfer of lipids and apolipoproteins within the plasma compartment. Abetalipoproteinemia (ABL), a genetic disease in which apoB is absent from the plasma and HDL are the sole plasma lipoproteins, is a model for the investigation of HDL metabolism without modification by apoB-containing lipoproteins. Apolipoproteins A-I and E are two of the major apolipoproteins in HDL. Plasma apoA-I levels, but not apoE levels, have been reported to be decreased in patients with ABL. Furthermore, HDL from ABL patients is enriched in apoE compared with normal subjects. The purpose of the present study was: 1) to elucidate the metabolic basis of the low apoA-I levels in ABL; 2) to determine whether in vivo apoE production rates are normal in the absence of apoB-lipoprotein secretion; and 3) to test the hypothesis that apoE influences apoA-I and HDL catabolism in ABL. 131I-labeled apoA-I and 125I-labeled apoE were reassociated with autologous lipoproteins and injected into two unrelated ABL patients and control subjects. The mean residence time of apoA-I in ABL (2.4 days) was significantly decreased by nearly 50% compared with control subjects (4.7 +/- 0.6 days). ApoA-I production rates were also significantly decreased by 40% in ABL (7.1 mg/kg-d) compared with control subjects (11.8 +/- 1.7 mg/kg-d). The mean residence time of apoE in ABL (0.50 days) was somewhat shorter than that of control subjects (0.66 +/- 0.15 days), whereas the mean apoE production rate in ABL (2.14 mg/kg-d) was not substantially different from that of control subjects (1.55 +/- 0.62 mg/kg-d). HDL subfractions LpA-I and LpA-I:A-II were isolated using immunoaffinity chromatography. In contrast to the normal metabolism, apoA-I in LpA-I:A-II particles was catabolized at a faster rate than apoA-I in LpA-I, accounting for the greater decrease of plasma LpA-I:A-II relative to LpA-I in the ABL patients. HDL subfractions with and without apoE were also isolated using anti-apoE immunoaffinity chromatography. Labeled apoA-I in apoE-containing HDL was catabolized faster than that in HDL without apoE. Among the three different forms of apoE, the apoE monomer was catabolized at the fastest rate, the apoE homodimer at an intermediate rate, and the apoE-A-II heterodimer had the slowest rate of catabolism.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7852858

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  11 in total

1.  Effects of Replacing Dietary Monounsaturated Fat With Carbohydrate on HDL (High-Density Lipoprotein) Protein Metabolism and Proteome Composition in Humans.

Authors:  Allison B Andraski; Sasha A Singh; Lang Ho Lee; Hideyuki Higashi; Nathaniel Smith; Bo Zhang; Masanori Aikawa; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-26       Impact factor: 8.311

2.  Dietary unsaturated fat increases HDL metabolic pathways involving apoE favorable to reverse cholesterol transport.

Authors:  Allyson M Morton; Jeremy D Furtado; Carlos O Mendivil; Frank M Sacks
Journal:  JCI Insight       Date:  2019-04-04

3.  Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.

Authors:  Allyson M Morton; Manja Koch; Carlos O Mendivil; Jeremy D Furtado; Anne Tjønneland; Kim Overvad; Liyun Wang; Majken K Jensen; Frank M Sacks
Journal:  JCI Insight       Date:  2018-02-22

4.  Protein-Defined Subspecies of HDLs (High-Density Lipoproteins) and Differential Risk of Coronary Heart Disease in 4 Prospective Studies.

Authors:  Frank M Sacks; Liang Liang; Jeremy D Furtado; Tianxi Cai; W Sean Davidson; Zeling He; Robyn L McClelland; Eric B Rimm; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-09-10       Impact factor: 8.311

5.  Effect of obesity, serum lipoproteins, and apolipoprotein E genotypes on mortality in hospitalized elderly patients.

Authors:  Filomena Addante; Daniele Sancarlo; Massimiliano Copetti; Carlo Scarcelli; Maria Grazia Longo; Valeria Niro; Giulia Paroni; Fabio Pellegrini; Luigi Fontana; Alberto Pilotto
Journal:  Rejuvenation Res       Date:  2011-04       Impact factor: 4.663

Review 6.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

7.  HDL (High-Density Lipoprotein) Subspecies, Prevalent Covert Brain Infarcts, and Incident Overt Ischemic Stroke: Cardiovascular Health Study.

Authors:  Manja Koch; Sarah A Aroner; Annette L Fitzpatrick; W T Longstreth; Jeremy D Furtado; Kenneth J Mukamal; Majken K Jensen
Journal:  Stroke       Date:  2021-10-14       Impact factor: 7.914

8.  Sex-specific interaction between APOE genotype and carbohydrate intake affects plasma HDL-C levels: the Strong Heart Family Study.

Authors:  M J Mosher; L A Lange; B V Howard; E T Lee; L G Best; R R Fabsitz; J W Maccluer; K E North
Journal:  Genes Nutr       Date:  2008-03-29       Impact factor: 5.523

Review 9.  Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.

Authors:  Alpo Vuorio; Matti J Tikkanen; Petri T Kovanen
Journal:  Vasc Health Risk Manag       Date:  2014-05-06

10.  Apolipoprotein gene polymorphisms and plasma levels in healthy Tunisians and patients with coronary artery disease.

Authors:  Raoudha Bahri; Esther Esteban; Pedro Moral; Mohsen Hassine; Khaldoun Ben Hamda; Hassen Chaabani
Journal:  Lipids Health Dis       Date:  2008-11-17       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.